Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia

Last updated: November 4, 2025
Sponsor: Spaulding Rehabilitation Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colic

Heartburn

Bowel Dysfunction

Treatment

taVNS

Health Education

Skills Building

Clinical Study ID

NCT06360900
2024P000849
R01DK136243
  • Ages 18-65
  • All Genders

Study Summary

The study aims at evaluating physiological and patient-reported outcomes for a dual intervention approach including a stimulation device and support therapy in patients with functional dyspepsia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age 18-65 years old (inclusive)

  • Ability to give written consent and participate in behavioral intervention inEnglish

  • Willingness to attend weekly treatment sessions over live video, dailyself-administered transcutaneous auricular vagus nerve stimulation (taVNS) sessions,and engage in homework during treatment

  • Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session

  • Diagnosis according to the Rome IV criteria for both epigastric pain syndrome andpostprandial distress syndrome subtypes

  • Stable medical treatment for functional dyspepsia (FD) during 1 month before thestudy and during the study period

Exclusion

Exclusion Criteria:

  • Previous receipt of cognitive behavioral therapy (CBT) for gastrointestinal symptoms

  • Enteral or parenteral feeding

  • Previous gastrointestinal surgery, electrolyte disturbances, kidney dysfunction,renal insufficiency, or iron overload disorders

  • Estimated Glomerular Filtration Rate (eGFR) < 60

  • Medications that affect gastrointestinal motility in addition to medications orproducts containing tetrahydrocannabinol (THC) will be stopped at least 7 days priorto the start of the study and for the duration of the study. However,anti-depressants (SSRI's, TCA's) may be allowed in order to reduce the risk ofworsening neuropsychiatric disease, though it will be up to the study team and thePrincipal Investigator whether subjects on anti-depressants will be able toparticipate in the study

  • Intellectual disability by history

  • Diabetes, mitochondrial disease, severe autonomic dysfunction, and small fiberpolyneuropathy

  • No active clinical acupuncture therapy

  • Illicit drugs or opioid usage

  • History of arrhythmias

  • Current pregnancy/breastfeeding

  • Contraindications for magnetic resonance imaging (MRI) (implanted ferromagneticobjects, claustrophobia)

  • Weight > 450 lbs. (limit of the MRI table)

  • Allergy to pineapple (used in the test meal during MRI)

  • Any other condition interfering with study requirements, according to theInvestigator

Study Design

Total Participants: 80
Treatment Group(s): 8
Primary Treatment: taVNS
Phase:
Study Start date:
October 29, 2025
Estimated Completion Date:
March 31, 2029

Connect with a study center

  • Massachusetts General Hospital

    Boston 4930956, Massachusetts 6254926 02129
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.